Epify
Latest round
- Seed
Last raised
- Sep 2019
Total raised
- $0.6M
Investors
- 2
About Epify
Based in Limburg, Netherlands, and founded in 2019, Epify BV is a company that focuses on facilitating cancer diagnosis and personalized treatments through epigenetic biomarkers. The company was founded by Manon van Engeland and Wim van Criekinge. The company specializes in the development of epigenetic biomarkers that regulate gene activity and are associated with various types of cancer. These biomarkers have been the focus of efforts to enable less invasive cancer detection and early intervention. Epify's goal is to leverage these biomarkers for earlier and more precise detection, enabling personalized oncology and offering improved prospects for cancer patients.
Who invested in Epify
2 investors across 1 round
See all investors in Epify
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Sep 25, 2019
Amount
$0.6M
Investors
Questions about Epify
Who invested in Epify?
Epify has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Epify raised?
Epify has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Epify last raise money?
Epify's most recent round on record is a Seed, in Sep 2019.
What does Epify do?
Based in Limburg, Netherlands, and founded in 2019, Epify BV is a company that focuses on facilitating cancer diagnosis and personalized treatments through epigenetic biomarkers.
Where is Epify headquartered?
Epify is headquartered in Maastricht, Netherlands.
Which VCs invest in companies like Epify?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Epify's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Epify? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.